Systemic sclerosis
Therapeutic area
Dermatology
Rare disease
Yes
- Definition
- A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Systemic sclerosis
- Therapeutic area
- Dermatology
- systemic sclerosis
- Scleroderma
- SSc
- Scleroderma, systemic
- Systemic Scleroderma
- systemic Scleroderma
- systemic scleroderma
- systemic sclerosis
- SSc, diffuse sclerosis
- Scleroderma, diffuse
- diffuse Scleroderma
- diffuse sclerosis
- Severity
- Severe
- Dermatology
- Immunology
- Rheumatology
- MONDO ID
- MONDO:0005100
- Parent condition
- MONDO:0005093
Related records
Broader conditions (10)
- Autoimmune disease
- Connective tissue disorder
- Disease
- Disease by body system or component
- Human disease
- Immune system disorder
- Integumentary system disorder
- Rheumatic disorder
- Scleroderma
- Skin disorder
Narrower conditions (7)
- CREST syndrome
- Diffuse cutaneous systemic sclerosis
- Diffuse scleroderma
- Limited cutaneous systemic sclerosis
- Limited systemic sclerosis
- Pulmonary systemic sclerosis
- Scleroderma, familial progressive
Trials (749)
- "As Required" Oral Sildenafil in Raynaud's Phenomenon
- "Pulmonary Rehabilitation Program in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis"
- 6-minute Pegboard Ring Test in Patients With Scleroderma
- 7.0 Tesla Resonance Magnetic Imaging of the Hand in Systemic Sclerosis
- 89Zr-Oxine-RY_SW01 Cell Injection for the Treatment of Systemic Sclerosis
- A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
- A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
- A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
- A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
- A Clinical Trial for CTD-ILD Treatment
- A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
- A Comparison Between Two Educational Methods in the Rehabilitation of the Microstomia in Systemic Sclerosis
- A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
- A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
- A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
- A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
Approved drugs (3)
- Bosentan
- Nintedanib esylate
- Tocilizumab
Drugs in development (63)
- Abatacept Phase 1
- Abituzumab Phase 2
- Albumin human Phase 2
- Avenciguat Phase 2
- Belimumab Phase 2
- Bermekimab Phase 2
- Bersiporocin Phase 1
- Bersiporocin hydrochloride Phase 1
- Brodalumab Phase 1
- Buspirone Early phase 1
- Clopidogrel Phase 2
- Cyclophosphamide Phase 3
- Divalproex sodium Phase 1
- Divozilimab Phase 3
- Etrinabdione Phase 2
- Filgrastim Phase 3
- Fipaxalparant Phase 2
- Fludarabine Phase 3
- Fludarabine phosphate Phase 2
- GSK-2330811 Phase 2